Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAGTIME: Raltegravir intensification and gut microbiota in chronic HIV-1 infection
2016-002722-36Phase 3Active
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Raltegravir intensification with Placebo (2 arms). Primary endpoint: Increase in bacterial richness (observed species). Started Jan 2017; status: active.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2016-002722-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002722-36.